Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib
US-2017369528-A1 · Dec 28, 2017 · US
US11958882B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11958882-B2 |
| Application number | US-201816494165-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 14, 2018 |
| Priority date | Mar 14, 2017 |
| Publication date | Apr 16, 2024 |
| Grant date | Apr 16, 2024 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed herein are methods of preparing a composition comprising crystalline biomolecules, for example, crystalline antibodies. In exemplary embodiments, the method comprises forming a fluidized bed of crystalline biomolecules using, for example, a counter-flow centrifuge to exchange buffer and/or to concentrate the crystalline biomolecules in a solution. Also provided are methods of detecting crystalline biomolecules and/or amorphous biomolecules in a sample.
Opening claim text (preview).
What is claimed is: 1. A method of preparing a composition comprising crystalline biomolecules, comprising: a) forming a fluidized bed of crystalline biomolecules in a rotating chamber comprising an inlet and an outlet, wherein the fluidized bed is created by rotating the chamber about a substantially horizontal axis to create a centrifugal force (F centrifugal ) in said chamber, flowing a first stream of a first solution through the inlet in a direction opposite to the direction of the F centrifugal and at a first flow rate (FR1) having a force (F FR1 ) which counter balances F centrifugal , and collecting the first solution from the chamber while substantially maintaining the formation of the fluidized bed of crystallized biomolecules; b) performing step (i), (ii), or (iii): i. flowing a second stream of a second solution to replace the first stream of the first solution while substantially maintaining the formation of the fluidized bed of crystallized biomolecules; ii. concentrating the crystallized biomolecules within a region of the chamber by changing FR1 to a second flow rate (FR2) having a force (F FR2 ) which is less than F centrifugal or by increasing the speed of rotation of the chamber to increase F centrifugal to a level which is greater than F FR1 ; iii. a combination of step (i) and step (ii); and c) flowing a second stream into the chamber through the outlet in a direction which is parallel to the direction of the F centrifugal to crystalline remove the crystalline biomolecules from the chamber. 2. The method of claim 1 , wherein F centrifugal is 1000 g during at least step (i). 3. The method of claim 1 , wherein the feed volume of the second stream of the second solution is about 50 to about 500 ml during step (i). 4. The method of claim 1 , wherein (A) the number of volumes of the first solution per chamber is 2 or more during step (i), (B) FR1 is about 50 ml/min to about 150 ml/min during step (i), (C) the first solution is a hypertonic crystallization buffer, (D) the second solution is an isotonic formulation buffer, (E) the second solution is an isotonic formulation buffer, (F) the F centrifugal is 1000 g during step (ii), (F) the feed volume of the second stream of the second solution is about 100 to about 500 ml during step (ii), (G) the number of volumes of the first solution per chamber is 1 or 2 during step (ii), (H) FR2 is about 10 ml/min to about 50 ml/min during step (ii), (I) the concentration of the crystalline biomolecules is increased at least 2-fold, (J) the method comprises decreasing F centrifugal to a level of about 5 g and about 20 g, (K) FR1 is controlled by a first pump and the first pump is set to about 10 ml/min to about 100 ml/min after step (b), (L) the rotating chamber is connected to a chamber peristaltic pump, (M) the method is carried out in an apparatus comprising more than one rotating chamber, (N) the crystalline biomolecule is a protein or comprises one or more polypeptide chains, or (O) any combination thereof. 5. The method of claim 4 , wherein the concentration of the crystalline biomolecules is increased at least 3-fold or at least 4-fold. 6. The method of claim 4 , wherein the chamber peristaltic pump is set to pump in the same direction of the first pump and F centrifugal . 7. The method of claim 4 , wherein the chamber peristaltic pump is set to about 75 ml/min, the first pump is set to about 50 ml/min, and F centrifugal is decreased to below 10 g. 8. The method of claim 4 , wherein the apparatus comprises at least 2, at least 4 or at least 6 rotating chambers. 9. The method of claim 8 , wherein steps (a) to (c) are carried out in more than one chamber. 10. The method of claim 9 , wherein crystalline biomolecules are removed from a chamber of the apparatus at a time distinct from when crystalline biomolecules are removed from another chamber of the apparatus.
by crystallization · CPC title
Stabilisation, fragmentation · CPC title
with liquid as a fluidising medium · CPC title
with fluidised bed containing a rotatable device or being subject to rotation {or to a circulatory movement, i.e. leaving a vessel and subsequently re-entering it} · CPC title
Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions (from molten solvents C30B9/00; by normal or gradient freezing C30B11/00; under a protective fluid C30B27/00) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.